Get the latest on Intellia Therapeutics’ Q3 2025 earnings: clinical hold impacts, nex-z safety updates, lonvo-z progress, and financial outlook.

With lifestyle disorders and non-communicable diseases on the rise, many people routinely undergo Liver Function Tests (LFTs). Seeing the words “LFT abnormal” on a report can be alarming. LFTs are a ...

A win-odds analysis is a statistical method used to analyze clinical trial data to evaluate the effectiveness of treatments. It provides a novel way to measure treatment effect by comparing the number ...

Bansal: As we just discussed, those that have these other metabolic disorders are at risk. And so that's your most at-risk ...

Patient portals are everywhere. According to the MyChart website, it gives patients access to their health information, ...

In the U.S., Vafseo® (vadadustat) is approved for the treatment of anemia due to CKD in adults who have been receiving dialysis for at least three months. Nephrologists in the U.S. began prescribing ...

KYGEVVI® (doxecitine and doxribtimine) powder for oral solution (2g/2g) is approved for the treatment of thymidine kinase 2 deficiency (TK2d) in adults and pediatric patients with an age of symptom ...

Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today ...